[1]陈一凡,李雁,褚岩,等.慢性阻塞性肺疾病的中药复方治疗专利现状及用药规律[J].西部中医药,2023,36(11):84-89.[doi:10.12174/j.issn.2096-9600.2023.11.19]
　CHEN Yifan,LI Yan,CHU Yan,et al.Patent Status of Chinese Medicine Compound for the Treatment of COPD and Medication Rules[J].Western Journal of Traditional Chinese Medicine,2023,36(11):84-89.[doi:10.12174/j.issn.2096-9600.2023.11.19]
点击复制

慢性阻塞性肺疾病的中药复方治疗专利现状及用药规律
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
36
期数:
2023年11期
页码:
84-89
栏目:
出版日期:
2023-11-15

文章信息/Info

Title:
Patent Status of Chinese Medicine Compound for the Treatment of COPD and Medication Rules
作者:
陈一凡, 李雁, 褚岩, 程淼, 曾燕鹏, 邹乔, 孔煜荣, 陈瑜
北京中医药大学东直门医院，北京 100700
Author(s):
CHEN Yifan, LI Yan, CHU Yan, CHENG Miao, ZENG Yanpeng, ZOU Qiao, KONG Yurong, CHEN Yu
Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing 100700, China
关键词:
慢性阻塞性肺疾病; 中药复方; 专利; 现状; 数据挖掘
Keywords:
COPD; Chinese medicine compound; patent; status; data mining
分类号:
R256.14
DOI:
10.12174/j.issn.2096-9600.2023.11.19
文献标志码:
A
摘要:
目的探析我国治疗慢性阻塞性肺疾病的中药复方专利分布现状及用药配伍规律。 方法基于中国知网专利数据库检索并筛选治疗慢性阻塞性肺疾病的中药复方专利，获取专利公开时间、申请人/申请单位所属地区以及复方用药等信息并进行规范化处理，在Excel软件中进行频次、频率统计，并应用数据挖掘软件进行关联规则、聚类和复杂网络分析。 结果共筛选出中药复方专利96个，专利数量基本呈平稳增长趋势，山东、河南、四川等地相关专利数量较多，涉及中药316味，药物四气以温、平性为主，五味多甘、辛，归经多属肺、脾经。频次较高的前10位中药分别为黄芪、陈皮、甘草、半夏、苦杏仁、茯苓、麻黄、白术、五味子、紫菀；常用药物组合为“半夏—陈皮—茯苓—甘草”“白术—陈皮—茯苓”“白术—半夏—茯苓”等；聚类分析共得到6类药物；核心药物网络由29味中药组成。 结论治疗慢性阻塞性肺疾病的中药复方专利申请日益受到重视，用药基本遵循扶正祛邪原则，以补肺健脾、理气化痰为主，兼顾疏风祛邪、温肾纳气、益气养阴、活血通络等治法。
Abstract:
ObjectiveTo explore the patent distribution and drug compatibility of traditional Chinese medicine (TCM) compound for the treatment of chronic obstructive pulmonary disease (COPD) in China. MethodsTCM compound patent for the treatment of COPD were searched and screened from the patent database of CNKI, to obtain the information including the patent disclosure time, the region of the applicant/application units and medication of TCM compound, and to conduct normalized processing, the frequency statistics were carried out in Excel software, and the data mining software was used for association rule analysis, cluster analysis and complex network analysis. ResultsA total of 96 patents were selected, and the number of patents basically showed a trend of steady growth, the number of patents in Shandong, Henan, Sichuan and other places was relatively high, involving 316 herbs, four properties of them were mainly warm and mild, the five flavors were mostly sweet and pungent, and the meridian tropism mainly belonged to lung and spleen. The top ten herbs with high frequency were Huangqi (Astragalus Membranaceus), Chenpi (Pericarpium Citri Reticulatae), Gancao (Glycyrrhiza Uralensis), Banxia (Pinellia Ternata), Kuxingren (Bitter Almond), Fuling (Poria Cocos), Mahuang (Ephedra), Baizhu (Atractylodes Macrocephala), Wuweizi (Schisandra Chinensis) and Ziwan (Aster); the commonly-used drug combinations were "Banxia-Chenpi-Fuling-Gancao", "Banxia-Chenpi-Fuling" and "Baizhu-Banxia-Fuling"; cluster analysis yielded six classes of drugs; the core drug network consisted of 29 herbal medicines. ConclusionGrowing attention has been paid to the patent application of TCM compound for the treatment of COPD, its application of the medicine basically follows the principle of enhancing healthy Qi and eliminating the pathogen, with the main focus on tonifying the lungs and strengthening the spleen, regulating Qi and resolving phlegm, and taking into account the treatment of dispelling wind and eliminating the evil, warming the kidneys and nourishing Qi, benefiting Qi and nourishing Yin, and activating blood circulation and dredging the collateral.

相似文献/References:

[1]王萍.慢性阻塞性肺病患者实施临床护理路径的疗效分析[J].西部中医药,2014,27(11):140.
[2]王 燕,孙凤英,倪 军.慢性阻塞性肺疾病患者非药物治疗依从性与生活质量相关性的研究[J].西部中医药,2015,28(03):89.
[3]郭晓燕,尹广超,陆城华,等.川芎平喘合剂对COPD患者血管内皮功能的调节作用[J].西部中医药,2015,28(05):1.
[4]王振伟,杨佩兰,沈丽,等.百部养肺煎膏治疗COPD稳定期患者的临床研究[J].西部中医药,2015,28(05):56.
[5]唐瑛,肖力强,江花,等.中药复方敷擦外治类风湿性关节炎的用药规律研究*[J].西部中医药,2013,26(05):57.
　TANG Ying,XIAO Liqiang,JIANG Hua,et al.Research on the Law of Medicine Application of TCM Compound in Treating Rheumatoid Arthritis for External Use[J].Western Journal of Traditional Chinese Medicine,2013,26(11):57.
[6]赵宇冰,林丽明.老年慢性阻塞性肺疾病患者缓解期的社区康复治疗[J].西部中医药,2012,25(08):59.
　ZHAO Yu-bing,LIN Li-ming.Community Rehabilitation Therapy for Senile Patients with COPD at Remission Stage[J].Western Journal of Traditional Chinese Medicine,2012,25(11):59.
[7]张旭辉,杨虹.咳喘宁胶囊治疗稳定期慢性阻塞性肺疾病的疗效评价[J].西部中医药,2016,29(03):1.
　ZHANG Xuhui,YANG Hong.Evaluation of Clinical Effects of KeChuanNing Capsules in Treating Chronic Obstructive Pulmonary Disease at Stable Stage[J].Western Journal of Traditional Chinese Medicine,2016,29(11):1.
[8]马红,王海红Δ,蒲小庆,等.中西医结合治疗 2 型糖尿病 68 例[J].西部中医药,2014,27(08):95.
[9]晏燕,孙建勤,姜冰玉,等.中西医结合治疗老年慢性阻塞性肺疾病急性加重期的临床疗效[J].西部中医药,2016,29(07):96.
　YAN Yan,SUN Jianqin,JIANG Bingyu,et al.Clinical Effects of Integrative Medicine in Treating Chronic Obstructive Pulmonary Disease of Senile Patients at Acute Exacerbation[J].Western Journal of Traditional Chinese Medicine,2016,29(11):96.
[10]施巍,苟小军,王道才,等.刺络放血法治疗慢性阻塞性肺疾病急性加重期48例[J].西部中医药,2017,30(02):96.
　SHI Wei,GOU Xiaojun,WANG Daocai,et al.Blood-letting Therapy in Treating 48 Cases of Chronic Obstructive Pulmonary Disease at Acute Exacerbation Stage[J].Western Journal of Traditional Chinese Medicine,2017,30(11):96.

备注/Memo

备注/Memo:
陈一凡（1996—），男，在读博士研究生。研究方向：呼吸系统疾病的中西医结合防治。国家重点研发计划项目（2018YFC1704100，2018YFC1704101）；北京中医药薪火传承“3+3”工程项目（2016-SZ-B-34）；北京中医药大学东直门医院横向课题（HX-DZM-2017019）。
更新日期/Last Update: 2023-11-15